Bayer AG announced that BlueRock Therapeutics successfully administered the first dose of its investigational pluripotent stem cell-derived dopaminergic neurons, named DA01, to a Parkinson’s disease patient in their open-label Phase I clinical safety and tolerability study.
[Bayer AG (BusinessWire, Inc.)]
7753456
{7753456:nan}
apa
50
1
163230
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
